The Trump administration has been conducting a restructuring of the US Department of Health and Human Services as well as a ...

The European Commission has approved Eisai and Biogen's Leqembi for a subset of patients with early-stage Alzheimer's disease, setting it up to become the first amyloid-targeting drug to reach the ...

Recent examples include Eisai and Biogen's efforts to develop an injectable version of new Alzheimer's disease therapy Leqembi (lecanemab), which has seen slow sales growth since launch ...